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Glioblastoma multiforme is a malignant tumor that grows in the human brain. Patients 
diagnosed with Glioblastomas (GBM) require very extensive and invasive treatment that 
includes surgery, chemotherapy, and radiation. Although these treatments are effective for other 
types of cancer, the rate of recurrence for Glioblastomas are extremely high. After being 
diagnosed, patients survive an average of 12-15 months afterwards (Ogura, et. al.,). The believed 
reason for this rate are the Glioblastoma stem cells present in the tumor prior to treatment. These 
stem cells are essentially identical to Glioblastoma cells that make up the bulk of the tumor, 
however, they have certain characteristics that allow them to have resistance to cancer 
treatments. It is difficult to identify stem cells because they are relatively rare and there is an 
absence of markers to identify them, increasing the difficulty to study them. Stem cells also show 
continual cell genesis in the central nervous system resulting in the production of functional 
progeny, allowing for the return of the malignant Glioblastoma tumor (Identification and 
Characterization of Neural Stem Cells: Why is this so darned difficult?, 2010). Current research 
in this subject has become especially pressing since there is a promise of a cure for 
Glioblastomas through STEM cells. Research with STEM cells in order to decrease its resistance 
to radiation is the main focus. Therefore, through this project we hoped to contribute some 
understanding and insight for better treatment options for GBMs. 
The first step in this experiment was to culture the GBM cells in a DMEM:F12 medium 
that was supplemented with 10% fetal bovine serum and penicillin/streptomycin. Next, these 
cells were then formed into cell spheres by being placed in a neural stem cell medium, 
containing recombinant human epidermal growth factor, basic fibroblast growth factor, and B27 
supplement, which was changed every two days. The U87 cell line spheres began growing 
within 3-5 days and the U251 cell line spheres took up to two weeks. Next, the expression of the 
cancer stem cell markers were tested. This was done by qPCR by RNA extraction. There are 
multiple possible markers to observe however, the most common found in the literature review 
was CD133, Musashi, and Nestin. Unfortunately, no single marker had been found to be 
sufficient to confer stem-like properties. Therefore, a combination of different markers must be 
used in future tests to determine these characteristics. A clonogenicity assay was performed on 
the cells to prove their ability to self-renew. In this step, one cell was plated per plate and 
allowed to replicate. The cells were passaged every 1-2 weeks for up to 4 passages, and U87 
spheres cells formed clones within the plates, proving that characteristic. In order to further 
prove the characteristics of self-renewal and proliferation, TEM pictures were taken of the cells 
on different days to see their growth rate. The U251 cells, that were irradiated, actually 
continued to grow, which is what was expected. The reason that GBM tumors reoccur so 
frequently is because the stem cells are essentially resistant to radiation, which is was what 
shown in this process. Another key characteristic of stem cells is their lack of organelles. So, it 
was determined that our cells also lacked organelles after careful observation of the ultrastructure 
through imaging. Lastly, in order to prove that the stem cells can differentiate into different cell 
types, a multipotency assay was performed. In this test, we stained the bulk cells to show the 
GFAP marker, which we found to be successful.  
Dr. Yasui and I were very happy with our results over the length of the experiment. 
Although we cannot say we definitively grew stem cells, the data and results we have at this 
point is very promising. From here, we will continue to perform the necessary tests until we 
prove the cells we grew are indeed stem cells. This summer we plan to carry out a tumorgenicity 
assay in which we will inject the stem cells into immunocompromised mice. If a tumor grows in 
that place then we can finally say we grew stem cells. After that, we will then incorporate the 
stem cells into further novel therapeutic approaches in hopes of developing a better method of 
treatment for patients with GBMs.  
Participation in the SEF program has allowed me to explore my academic interests 
further in an environment that is not a controlled classroom. This is extremely significant since 
experiences like this one will prepare me for my professional future and allow me to develop 
skills and characteristics I would lack otherwise. Working closely with a successful professor has 
given me insight into academia and has allowed me to develop close relationships with not only 
Dr. Yasui but other students as well, which has already proven to be very beneficial for my 
academic career.  
Other Materials 
 
This is the clonogenicity assay in which we proved the cells’ ability to self-renew. 
 Above are the ultrastructure pictures of the U87 cell line (left) and the U251 cell line (right). 
 
Above is an image of the U251 bulk tumor cells which was taken during the multipotency assay 
to prove the cells’ differentiation potential.  
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Culture plates 596.77 
Packets of powered growth medium 81.79 
Stem cell growth supplements and growth factors  1,197.92 
CSC markers 638.00 
TOTAL 2,514.48 
 
All listed prices reflect NIU’s negotiated contract prices from Fisher 
Scientific.  All commodities listed are necessary to grow and maintain CSCs 
(Cancer Stem Cells).  Two kind of culture plates are included in the culture 
plate category.  These culture vessels are specifically treated to permit CSC 
growth into sphere cultures or for a limiting dilution assay used to determine 
the proportion of CSCs in the population. 
 
The powered growth medium packets are conveniently packaged to make 1 
liter of growth medium.  We save commodity dollars by filter sterilizing our 
own medium.   
 
The stem cell growth supplements and growth factors are essential elements 
for CSC growth.  These include B27 supplements, epidermal growth factor 
and fibroblast growth factor. 
 
CSC markers will be used to confirm that we have cultured CSCs.      
 
The small overage above $2500 will be covered by commodity funds 
provided by Dr. Yasui’s Biological Sciences Departmental Commodities 
allocation. 
 
 
 
 
